| Document |
Document Title |
|
WO/2009/087981A1 |
Disclosed is a polymerizable compound which can be obtained by a simpler process. The polymerizable compound is represented by formula (1) or (2). [Rf-{R1-X0-(CO)t-R2-}q]mX1-R3-Z (1) Rf-R1-X2-CO(NH)r-R3-Z (2) In the formulae, Rf represen...
|
|
WO/2009/081789A1 |
A compound that is useful as an agent in the prevention and treatment of circulatory system, nervous system, metabolic, reproductive system, and gastrointestinal diseases. Formula (I) is a compound represented by the following: [structur...
|
|
WO/2009/078268A1 |
Disclosed is a gelling agent containing a fluoroalkyl derivative, a small amount of which can gelatinize or solidify various organic solvents. Specifically disclosed is a gelling agent for organic liquids, which contains a fluoroalkyl de...
|
|
WO/2009/073592A2 |
The present invention provides fluoroalkyl amines represented by the formula R1-Q-S(O)x-C(H),(CH3)r(CH2)z+(1-1)-NHR and fluoroalkyl isocyanates and isothiocyanates represented by the formula RrQ-S(O)x-C(H)l(CH3)r(CH2)Z+(1-1)-N=C=X1, wher...
|
|
WO/2009/070873A1 |
Substituted 2-naphthoic acids of structural formula I are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this recep...
|
|
WO/2009/066952A1 |
Provided are a monomer for a proton-conducting polymer having an acid group in aside chain thereof, a proton-conducting polymer prepared using the monomer, a method of preparing the proton-conducting polymer, an electrolyte membrane comp...
|
|
WO/2009/063427A1 |
Compounds that may have anti-inflammatory activity have the general formula (I): Wherein R1, R2, R3 are each independently H or a C1-4 alkyl group or a C2-4 acyl group; R4 and R5 are each independently H or a group of formula -SO3R6, whe...
|
|
WO/2009/061744A2 |
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (K...
|
|
WO/2009/049961A2 |
The present invention refers to new NO-donors aspirin derivatives, a process for their preparation and pharmaceutical compositions containing them.
|
|
WO/2009/049845A2 |
Novel aromatic compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, R5, G1, G2, Q1, Q2, Y1, Y2, Y3 and Y4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes for preparing...
|
|
WO/2009/045488A2 |
The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms of armodafinil, pharmaceutical formulation thereof, and method of treating excessive sleepiness using the formulations of the inven...
|
|
WO/2009/043784A1 |
Compounds of the formula (I) wherein Ar1, Ar2, R1 and R2 are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.
|
|
WO/2009/040590A1 |
For the manufacturing of a complex product with advanced assimilation efficacy, including methyl-methionine sulphonium, carboxyl-uracil, paraaminobenzoic acid, dimethyl-sulfoxide and poliethoxy castor oil, and its utilization.
|
|
WO/2009/038463A1 |
The invention relates to new, highly efficient UV - absorbing compounds, a process for their manufacturing and to uses of these UV - absorbing compounds. The UV - absorbing compounds are in particular UV - A - absorbing compounds accordi...
|
|
WO/2009/030752A1 |
The present invention relates to compounds of formula (I) : as well as to cosmetic and pharmaceutical compositions containing such a compound.
|
|
WO/2009/027004A1 |
The invention relates to a novel thermodynamically stable crystal modification of 2-({2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)me
thyl]phenyl}carbonyl)cyclohexane-1,3-dione. A thermodynamically stable crystal modification of...
|
|
WO/2009/025791A2 |
The invention encompasses processes for obtaining pure armodafinil substantially free of disulfide impurities that is suitable for use on an industrial scale. In particular, a processes for purifying armodafinil from bis(diphenylmethyl)d...
|
|
WO/2009/024863A2 |
Disclosed herein is a convenient, commercially viable and environmentally friendly process for the preparation of Armodafinil. The present invention also provides an improved, commercially viable and industrially advantageous process for...
|
|
WO/2009/022681A1 |
Disclosed is a positive resist composition which is good in pattern shape, line-edge roughness, pattern collapse, sensitivity and resolution in conventional exposure (dry exposure), liquid immersion exposure and double exposure. Also dis...
|
|
WO/2009/018824A1 |
A composition comprising specific beta-blockers such as bisoprolol and nebivolol for the treatment of insomnia and/or another sleep disorder. The composition should be given in such an amount that it causes a less than 40 % decrease in t...
|
|
WO/2009/014268A1 |
There is provided a fluorine-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein G represents an oxygen atom or a sulfur atom; R2 represents a C1-C4 chain hyd...
|
|
WO/2009/010156A2 |
The invention relates to compounds of formula (I) or the salts thereof, wherein Q is a (hetero)aromatic radical having up to 6 ring atoms, the ring of the heteroaromatic radical comprising 1, 2, 3 or 4 nitrogen atoms or 1 sulphur atom or...
|
|
WO/2009/008905A1 |
Compounds having the formula : (I) wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of phenoxy-acetic acids and analogs capable of inhibiting the lethal effects of infection by anthrax b...
|
|
WO/2009/009041A2 |
The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
|
|
WO/2009/005110A2 |
There is provided a halogen-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein, m represents 0, 1 or 2, n represents 0, 1 or 2, A represents optionally subst...
|
|
WO/2008/157216A1 |
The present invention provides a process for the manufacture of an arylmethyl-sulfonylarene, R1CH2SO2R2, wherein R1 and R2 are each independently an optionally substituted phenyl or naphthyl group which process comprises reacting an aryl...
|
|
WO/2008/153159A1 |
It is intended to provide a novel amine compound represented by the following general formula (I), a pharmaceutically acceptable acid addition salt thereof, a hydrate thereof or a solvate thereof, which has an excellent peripheral blood ...
|
|
WO/2008/151211A1 |
The present invention relates to A compound of the formula Ia wherein in any of its stereoisomers forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as desc...
|
|
WO/2008/148468A1 |
The present invention relates to di(hetero)arylcyclohexane derivatives of the formula (I), in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmaceutical active compou...
|
|
WO/2008/149141A2 |
The present invention relates to a process for the preparation of polymorphic forms of the R- and S-enantiomers of modafinil, R-(-)-2-benzhydrylsulfinylacetamide and S-(+)-2- benzhydrylsulfinylacetamide respectively.
|
|
WO/2008/143338A1 |
There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods represented by the formula (I): wherein, R1 represents a C3-C10 alkenyl group optionally substituted with at least one halogen atom...
|
|
WO/2008/143333A1 |
There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods which is represented by formula (I): wherein R1 represents a C3-C6 haloalkyl group having at least one fluorine atom and at least o...
|
|
WO/2008/143332A1 |
There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods represented by the formula (I): wherein, R1 represents a C1-C5 haloalkyl group having at least one fluorine atom, R2 represents a C...
|
|
WO/2008/133112A1 |
Disclosed is (1) a sulfone compound having a propargyl group. Also disclosed is (2) a nonaqueous electrolyte solution for lithium secondary batteries, which is obtained by dissolving an electrolyte in a nonaqueous solvent, which nonaqueo...
|
|
WO/2008/123207A1 |
[PROBLEMS] To provide a compound useful as a therapeutic agent for chronic renal failure or diabetic neuropathy. [MEANS FOR SOLVING PROBLEMS] Disclosed is an ornithine derivative having an EP4 receptor antagonistic activity. In the compo...
|
|
WO/2008/119176A1 |
This invention describes an amidation process whereby amino acids of the Formulae IIA or IIB can be activated and treated with an amine in the presence of a base to yield amides of the Formula (I), without loss of optical purity.
|
|
WO/2008/114275A2 |
The present invention provides novel anthranilic acid derivative useful as potential anticancer agent. More particularly, the present invention relates novel anthranilic acid derivative of general formula (8), R' = alkyl-2-methoxyphenyl ...
|
|
WO/2008/115999A1 |
This invention is directed to compounds of formula (I), wherein A, B, m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodr...
|
|
WO/2008/111563A1 |
[PROBLEMS] To produce an optically active sulfoxide compound which is useful as an intermediate or a starting material for the synthesis of a physiologically active substance such as a pharmaceutical agent, at high optical purity. [MEANS...
|
|
WO/2008/110308A2 |
Cyclohexanedione compounds, and derivatives thereof, which are substituted in 5-position, are suitable for use as herbicides.
|
|
WO/2008/110621A1 |
The present invention relates to two crystalline forms of 2-[2-chloro-4-methylsulfonyl-3-(2,2,2-trifluoro-ethoxymethyl
)benzoyl]cyclohexan-1,3-dione, which is also known under the common name tembotrione. The invention also relates to a ...
|
|
WO/2008/108735A1 |
The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and d...
|
|
WO/2008/109697A2 |
Compounds of Formula I, wherein Ar, L, m, R1, R2, R3, W, X, Y, Z are as defined in the claims, are described that are active on at least one of PPARα, PPARδ and PPARγ, which are useful for therapeutic and/or prophylactic methods invol...
|
|
WO/2008/093711A1 |
Disclosed is a solid-phase oxidation reaction system for an organic compound, which has such advantages that the system does not require any organic solvent which may adversely affect the global environment, has a high product yield, ena...
|
|
WO/2008/093506A1 |
Disclosed is a recording material composition which comprises a crosslinked diphenylsulfone compound and a monohydroxydiphenylsulfone derivative and is excellent in color-developing property and image storage stability. Specifically disc...
|
|
WO/2008/078811A1 |
It is intended to provide a novel herbicide which has a wide range of applications to arable and non-arable lands and the like, and various methods for application to soil treatment, stem and leaf treatment and the like, and exhibits an ...
|
|
WO/2008/078674A1 |
Disclosed is a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, wherein a carbon atom having an asterisk has an R-configuration; R1 and R2 independently represent a hydrogen atom, a halogen atom, an ...
|
|
WO/2008/076256A1 |
The present invention discloses prodrugs of chloramphenicol, thiamphenicol and their analogs, as well as pharmaceutically acceptable salts thereof, including nitrogen-containing esters of both alcohol groups. These prodrugs have the Form...
|
|
WO/2008/075672A1 |
Disclosed is a method for producing a tris(perfluoroalkanesulfonyl)methide acid salt represented by the formula [1], which comprises a step (a) for obtaining a reaction mixture by reacting a methyl magnesium halide represented by the for...
|
|
WO/2008/074132A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...
|
